BioLitec AG

biolitec- earnings more than tripled to cumulated 3.7 million In the third quarter - revenue growth in the USA increased to + 83%

(lifepr) Jena, 31.05.2007, biolitec AG, Jena listed in the Prime Standard of the Frankfurt stock exchange (ISIN DE0005213409) increased the revenues to Euro 26.4 million during the first nine months of the business year 06/07 (previous year: Euro 19.5 million). EBIT increased by 321 % to Euro 3.7 million (previous year: Euro 0.9 million) and operating income increased from Euro 1.1 million to Euro 3.8 million. Gross profit amounted to Euro 18.2 million (last fiscal year: Euro 13.1 million). Net income amounted to Euro 3.2 million
(previous year: Euro 0.9 million) although the expenditures for research and development continued with 18% of revenue (e.g. for clinical studies on cellulite and cancer therapy) on a high level.

In the first nine months the laser business increased by 56%, the sales of disposables increased by 33%. According to the regional segmentation North American revenues increased by 70 % in the first nine months. Despite the dollar cutback the third quarter North American revenues (mainly in the US) increased by 83 %.

The current growth is mainly driven by sales of disposables especially in the fields of aesthetics and urology as well as by the increase of installed laser base (especially for the ELVeS™ vein treatment as well as for the benign prostate hyperplasia). Also, future growth is expected in the fields of aesthetics as well as urology.

For the remaining business year biolitec expects that the positive business development of the previous quarters will accelerate.
The strong increase of sales of our lasers in the last quarters forms the basis for an increasing growth dynamic for disposables in the coming quarters. Disposables form the main part of biolitec’s business and earnings. The laser sales will also develop dynamically
– as could be seen on the AUA (congress of the American Urological Association). The US-market traditionally leads the way and these trends will be adopted worldwide in the near future.

Weitere Meldungen dieses Unternehmens

• 28.11.2008 - biolitec AG erzielt in den ersten drei Monaten des Geschäftsjahres...
• 28.11.2008 - biolitec AG achieved consolidated revenue of Euro 7.4 million...
• 12.11.2008 - Krebsmedikament Foscan® der biolitec AG wird jetzt von niederländischen...
• 30.09.2008 - biolitec AG achieved consolidated revenue of Euro 35.4 million...
• 30.09.2008 - biolitec AG erzielt im Geschäftsjahr 2007/2008 Konzernumsatz...
• 08.07.2008 - biolitec AG führt mit LaEvita™-Bodyforming erfolgreich neue Laserbehandlung...